Heidi Cuthbert

Kiora Pharmaceuticals (NASDAQ:KPRX) licensed South Korean development and commercialization rights for its retinal therapy KIO-301 in ophthalmic indications to Chong Kun Dang Pharmaceutical (CKD).

Blockchain analytics firm Arkham has identified that the wallet pension-usdt.eth is holding an US$85 million short position on Ethereum (CRYPTO:ETH), opened at an average entry price of approximately US$1,700 and now sitting at an unrealised loss of approximately US$9.8 million as ETH approaches US$1,900.

Chemomab Therapeutics (NASDAQ:CMMB) reported second-quarter 2026 results and progress on its proposed all-stock merger with Scipher Medicine, with Chemomab shareholders expected to own about 32% of a combined company valued at $150 million.

TJX Companies (NYSE:TJX) reported second-quarter fiscal 2027 net sales of $15.2 billion, up 5% year over year, with consolidated comparable sales increasing 4%.

Merck (NYSE:MRK) and Moderna (NASDAQ:MRNA) announced positive Phase 3 results from the INTerpath-001 trial, with intismeran autogene combined with KEYTRUDA meeting its primary recurrence-free survival endpoint and key secondary distant metastasis-free survival endpoint in patients with resected stage IIB-IV melanoma.

Weibo (NASDAQ:WB) reported Q2 2026 net revenue of $453.8 million, up 2% year over year, as growth in value-added services offset lower advertising revenue.

Solana co-founder Anatoly Yakovenko proposed minting extra Solana (CRYPTO:SOL) to fund a company acquisition.

Polymarket US processed its first multi-leg sports trade on August 5, generating $7.4 million in volume.

Moneyme (ASX:MME) reported record originations of $1.23 billion for the financial year ended June 30, lifting its total loan book by 34%.

The Wyoming Stable Token Commission moved Frontier Stable Token (CRYPTO:FRNT) from LayerZero to Chainlink’s CCIP after a security review.